⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iii follicular thyroid cancer

Every month we try and update this database with for stage iii follicular thyroid cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNCT00005842
Cancer
trastuzumab
tipifarnib
18 Years - National Cancer Institute (NCI)
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyNCT00095836
Head and Neck C...
Gefitinib
18 Years - Massachusetts General Hospital
Iodine I 131 in Treating Patients With Thyroid CancerNCT00416949
Head and Neck C...
Patient-specifi...
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver MetastasesNCT00062348
Colorectal Canc...
Head and Neck C...
Metastatic Canc...
boronophenylala...
sodium borocapt...
conventional su...
18 Years - European Organisation for Research and Treatment of Cancer - EORTC
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid CancerNCT00415233
Head and Neck C...
recombinant thy...
Radiodine ablat...
16 Years - 80 YearsUniversity College, London
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerNCT00005842
Cancer
trastuzumab
tipifarnib
18 Years - National Cancer Institute (NCI)
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerNCT00095693
Anaplastic Thyr...
Insular Thyroid...
Recurrent Thyro...
Stage III Folli...
Stage III Papil...
Stage IV Follic...
Stage IV Papill...
sorafenib tosyl...
laboratory biom...
pharmacological...
fludeoxyglucose...
positron emissi...
dynamic contras...
18 Years - National Cancer Institute (NCI)
Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid CancerNCT01118065
Head and Neck C...
everolimus
18 Years - National Cancer Institute (NCI)
Iodine I 131 in Treating Patients With Thyroid CancerNCT00416949
Head and Neck C...
Patient-specifi...
18 Years - 100 YearsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine TherapyNCT00095836
Head and Neck C...
Gefitinib
18 Years - Massachusetts General Hospital
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerNCT00095693
Anaplastic Thyr...
Insular Thyroid...
Recurrent Thyro...
Stage III Folli...
Stage III Papil...
Stage IV Follic...
Stage IV Papill...
sorafenib tosyl...
laboratory biom...
pharmacological...
fludeoxyglucose...
positron emissi...
dynamic contras...
18 Years - National Cancer Institute (NCI)
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckNCT00005647
Head and Neck C...
paclitaxel
semaxanib
18 Years - Case Comprehensive Cancer Center
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497
Anaplastic Thyr...
Insular Thyroid...
Metastatic Para...
Recurrent Adeno...
Recurrent Basal...
Recurrent Esthe...
Recurrent Inver...
Recurrent Lymph...
Recurrent Lymph...
Recurrent Metas...
Recurrent Midli...
Recurrent Mucoe...
Recurrent Non-s...
Recurrent Parat...
Recurrent Saliv...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Squam...
Recurrent Thyro...
Recurrent Verru...
Stage III Folli...
Stage III Papil...
Stage III Saliv...
Stage III Squam...
Stage III Squam...
Stage III Verru...
Stage IIIB Non-...
Stage IV Lympho...
Stage IV Non-sm...
Stage IV Squamo...
Stage IV Squamo...
Stage IVA Adeno...
Stage IVA Basal...
Stage IVA Esthe...
Stage IVA Folli...
Stage IVA Inver...
Stage IVA Lymph...
Stage IVA Midli...
Stage IVA Mucoe...
Stage IVA Papil...
Stage IVA Saliv...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Squam...
Stage IVA Verru...
Stage IVA Verru...
Stage IVB Adeno...
Stage IVB Basal...
Stage IVB Esthe...
Stage IVB Folli...
Stage IVB Inver...
Stage IVB Lymph...
Stage IVB Midli...
Stage IVB Mucoe...
Stage IVB Papil...
Stage IVB Saliv...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Squam...
Stage IVB Verru...
Stage IVB Verru...
Stage IVC Adeno...
Stage IVC Basal...
Stage IVC Esthe...
Stage IVC Folli...
Stage IVC Inver...
Stage IVC Lymph...
Stage IVC Midli...
Stage IVC Mucoe...
Stage IVC Papil...
Stage IVC Saliv...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Squam...
Stage IVC Verru...
Stage IVC Verru...
Thryoid Gland N...
Thyroid Gland M...
Tongue Cancer
Untreated Metas...
gefitinib
- National Cancer Institute (NCI)
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid CancerNCT01164176
Head and Neck C...
everolimus
laboratory biom...
18 Years - Yonsei University
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid CancerNCT00415233
Head and Neck C...
recombinant thy...
Radiodine ablat...
16 Years - 80 YearsUniversity College, London
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: